Leukemia, Lymphocytic, Chronic, B-Cell
-
Subject Areas on Research
-
"Primum non nocere": the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia.
-
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
-
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
-
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
-
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
-
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
-
A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
-
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
-
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
-
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
-
Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.
-
Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
-
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.
-
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.
-
Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
-
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
-
Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
-
Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia.
-
Axillary lymph nodes: mammographic, pathologic, and clinical correlation.
-
B-lymphoblastic leukemia in a patient with chronic lymphocytic leukemia: Sequential development of biclonal B-cell neoplasms over a 23-year period in a single individual.
-
CD38 variation as a prognostic factor in chronic lymphocytic leukemia.
-
CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant.
-
Carcinogenicity of inhaled benzene in CBA mice.
-
Cardiac tamponade in a patient with chronic lymphocytic leukemia.
-
Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol.
-
Chasing cancer with chimeric antigen receptor therapy.
-
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
-
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
-
Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels.
-
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.
-
Chronic lymphocytic leukemia in African Americans.
-
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
-
Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia.
-
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
-
Clinical aspects of monoclonal B-cell lymphocytosis.
-
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
-
Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
-
Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection.
-
Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.
-
Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes.
-
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.
-
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
-
Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases.
-
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
-
Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia.
-
Detection of trisomy 12 by fluorescence in situ hybridization on archival cytopathologic material in chronic lymphocytic leukemia/small lymphocytic lymphoma.
-
Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
-
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).
-
Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL.
-
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
-
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.
-
Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.
-
Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India.
-
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
-
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
-
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
-
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
-
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
-
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
-
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
-
Fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia.
-
G-CSF for fever and neutropenia induced by chemotherapy.
-
Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia.
-
Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia.
-
Genetic susceptibility variants for chronic lymphocytic leukemia.
-
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
-
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
-
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.
-
Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers.
-
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.
-
Genomic stratification for the treatment of lymphomas.
-
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
-
Highlights from the 46 th annual meeting of the American Society of Hematology.
-
Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia.
-
Histiocytic/dendritic cell transformation of B-cell neoplasms: pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies.
-
Hypersensitivity of lymphocytes from chronic lymphocytic leukemia patients to ultraviolet light-C radiation.
-
IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria.
-
IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells.
-
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
-
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
-
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
-
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
-
IgG4-related tubulointerstitial nephritis associated with chronic lymphocytic leukemia.
-
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.
-
Immunoglobulin class switch recombination in chronic lymphocytic leukemia.
-
Immunologic aspects of monoclonal B-cell lymphocytosis.
-
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.
-
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
-
Individualizing treatment decisions for older adults with hematologic malignancies.
-
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
-
Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft.
-
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
-
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
-
Lipids and Their Effects in Chronic Lymphocytic Leukemia.
-
Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
-
Mantle zone lymphoma in a gastric glomus tumor.
-
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes.
-
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
-
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
-
Metachronous/concomitant B-cell neoplasms with discordant light-chain or heavy-chain isotype restrictions: evidence of distinct B-cell neoplasms rather than clonal evolutions.
-
MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference.
-
Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
-
Monoclonal B cell lymphocytosis.
-
Monoclonal B cell lymphocytosis: clinical and population perspectives.
-
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.
-
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
-
Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
-
Non-Hodgkin's lymphomas, version 1.2013.
-
Novel insights into the biology of CLL.
-
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
-
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
-
Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL.
-
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
-
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
-
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
-
Patterns of microRNA expression characterize stages of human B-cell differentiation.
-
Perifosine as a potential novel anti-telomerase therapy.
-
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
-
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
-
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
-
Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study.
-
Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.
-
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
-
Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
-
Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.
-
Progressive outer retinal necrosis.
-
Pseudohypoxemia in a patient with chronic lymphocytic leukemia.
-
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
-
Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
-
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
-
Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells.
-
Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study.
-
Renal lymphoma in an azotemic patient--usefulness of magnetic resonance imaging.
-
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
-
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
-
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
-
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
-
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
-
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.
-
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
-
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.
-
Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.
-
Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination.
-
Statin use and need for therapy in chronic lymphocytic leukemia.
-
Statins enhance efficacy of venetoclax in blood cancers.
-
Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.
-
T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications.
-
Telomerase activity in normal leukocytes and in hematologic malignancies.
-
The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.
-
The immunologic approach to analysis of malignant lymphoma. Mantle zone lymphoma of the ileocecal region.
-
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
-
The impact of the host on fungal infections.
-
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
-
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
-
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
-
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
-
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
-
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
-
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
-
Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture.
-
Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma.
-
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
-
Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study.
-
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
-
Keywords of People